Table 3.
Tumor Responses per Investigator and BICR Assessment (mRECIST)
| Best Response, n (%) | Investigator (n=62) | BICR (n=62) | ||||
|---|---|---|---|---|---|---|
| BCLC-A (n=6) | BCLC-B (n=21) | BCLC-C (n=35) | BCLC-A (n=6) | BCLC-B (n=21) | BCLC-C (n=35) | |
| Complete response | 3 (50) | 9 (42.9) | 8 (22.9) | 3 (50) | 7 (33.3) | 7 (20) |
| Partial response | 1 (16.7) | 9 (42.9) | 20 (57.1%) | 1 (16.7) | 9 (42.9) | 21 (60) |
| Stable disease | 2 (33.3) | 2 (9.5) | 4 (11.4) | 2 (33.3) | 3 (14.3) | 4 (11.4) |
| Progressive disease | 0 | 1 (4.8%) | 3 (8.6) | 0 | 1 (4.8) | 3 (8.6) |
| Not evaluable | 0 | 0 | 0 | 0 | 1 (4.8) | 0 |
| Objective response rate, n (%) | 4 (66.7) | 18 (85.7) | 28 (80) | 4 (66.7) | 16 (76.2) | 28 (80) |
| Disease control rate, n (%) | 6 (100) | 20 (95.2) | 32 (91.4) | 6 (100) | 19 (90.5) | 32 (91.4) |
| Conversion to resectable HCC, n (%) | 3 (50) | 11 (52.4) | 19 (54.3) | 3 (50) | 11 (52.4) | 19 (54.3) |
Abbreviations: BICR, blinded independent central review; mRECIST, modified Response Evaluation Criteria in Solid Tumors; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.